-
Sector Analysis
Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Chronic Urticaria Marketed and Pipeline Drugs Report Overview Chronic Urticaria (CU) is characterized by urticaria persisting continuously or intermittently for at least six weeks. CU includes chronic inducible urticaria (CIndU), also known as physical urticaria, and CSU. CSU is a mast cell-driven disorder characterized by the recurrent appearance of hives and/or angioedema persisting for more than six weeks. Key Mechanisms of Action (Marketed) ·      Receptor Antagonists ·      Receptor Agonists ·      Enzyme Inhibitors ·      Biological Factor Inhibitors ·      Protein and Peptide...
-
Product Insights
Chronic Urticaria or Hives Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Chronic Urticaria Or Hives - Global Clinical Trials Review, 2024" provides an overview of Chronic Urticaria Or Hives Clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Urticaria Or Hives. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Chronic Urticaria Or Hives - Drugs In Development, 2024
Empower your strategies with our Chronic Urticaria Or Hives – Drugs In Development, 2024 report and make more profitable business decisions. Chronic urticaria, also known as hives, are outbreaks of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.